SIA Elpis Reports 10.6% Revenue Decline Amid Strategic Shift to EU Markets

For SIA Elpis, the fiscal year marked a significant departure from the growth trajectory seen in 2024. According to information provided via “Firmas.lv,” the company’s turnover dropped to 47.095 million euros, a sharp contrast to the 52.708 million euros recorded in 2024—a year that had seen a 12.1% increase over 2023. The company’s bottom line took a harder hit, with profits contracting to 1.022 million euros, down from the 3.323 million euros reported previously, which represented a 65.3% increase over 2023 performance.

Geopolitical Pressures and Supply Chain Constraints

The company’s management cited a volatile international environment as a primary driver for the financial decline. In its annual report, the firm pointed to international sanctions that have complicated both the distribution of goods and the receipt of payments from Russia and Belarus. These barriers have effectively forced a reevaluation of the company’s operational reach. The management noted that the 2024 strategy, which involved analyzing the existing client base and shifting toward the European Union, was implemented to mitigate these external pressures.

Beyond regional sanctions, the firm identified broader macroeconomic instability as a factor in its rising operational expenses. The management report highlights how tensions between the United States and Iran have rippled through the global economy, specifically inflating energy costs and disrupting international shipping. These logistics challenges, coupled with fluctuating oil and gas prices, have placed upward pressure on both the company’s production costs and final consumer pricing worldwide.

Strategic Pivot Toward European Markets

In response to these headwinds, Elpis has begun shifting its long-term strategy. The company is actively moving away from its reliance on traditional partners in the east, opting instead to prioritize the European Union market. This transition, initiated in 2024, was designed to secure a more stable cash flow and build a new client base. Management explicitly stated that the 2024 strategy allowed the company to gain new clients and cooperation partners, providing a foundation for more stable financial operations.

Part of this expansion includes a tangible investment in regional growth: the company established a subsidiary in Romania during 2024. While the subsidiary was founded last year, the firm plans to begin active operations in the Romanian market this year. This move aligns with the company’s stated goal of increasing its medication export turnover, a key pillar of its recovery plan for the current year.

Internal Optimization and Ownership Structure

The company’s agenda for this year includes a focus on optimizing warehouse inventory levels and diversifying its product range with a new array of positions. By refining these internal logistics and continuing to monitor performance, the firm aims to improve its turnover metrics.

Elpis, which was originally registered in 1994, maintains a pamatkapitāls (share capital) of 213,428 euros. The ownership structure remains centralized under SIA J.L.Invest, which holds a 98% stake in the company. The shareholders of SIA J.L.Invest are Jānis Leitāns (55%), Igors Gockis (15%), Eduards Leitāns (15%), and Jurijs Leitāns (15%). The remaining 2% stake in Elpis is held by Aleksandrs Ozoliņš.

As the company moves forward, the success of its Romanian subsidiary and its ability to successfully pivot its export strategy will be central to its operational focus. The firm continues to emphasize the importance of optimizing internal processes and replenishing inventories to navigate the current climate of high logistics costs and global economic uncertainty.

Sources: Farmacija Mic, europesays.com.